Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 20, 2022

SELL
$5.46 - $8.29 $955 - $1,450
-175 Closed
0 $0
Q4 2021

Feb 04, 2022

SELL
$7.34 - $11.18 $1,651 - $2,515
-225 Reduced 56.25%
175 $1,000
Q3 2021

Nov 12, 2021

BUY
$6.49 - $9.91 $2,596 - $3,964
400 New
400 $4,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $841M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Resources Management Corp Portfolio

Follow Resources Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resources Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Resources Management Corp with notifications on news.